AI Summary
SL Science reported 2025 net revenue of $2.20 million, down 35% YoY as it pivoted Taiwan sales to wholesale. The company completed a business combination and Nasdaq listing on June 12, 2026, plus a $7.8 million PIPE, boosting financial flexibility to advance GDT and CD-19 programs toward IND in 2027. Cash declined to $1.26 million at year-end, underscoring near-term burn but improved liquidity post-listing.
Sentiment Rationale
New listing improves liquidity and visibility; substantial PIPE funds bolster research and development cadence; near-term catalysts include IND timing and regulatory progress, though ongoing losses and cash burn pose risk.
Trading Thesis
Near-term upside plausible on Nasdaq listing and PIPE; longer-term depends on IND/regulatory milestones.
Market-Moving
- Nasdaq listing increases SLBT liquidity and investor access.
- PIPE financing of $7.8 million provides runway for GDT/CD-19 programs.
- 2025 revenue decline and higher Opex may pressure near-term margins.
- Regulatory milestones: IND submission targeted for 2027.
Key Facts
- Net revenue 2025: $2.20m, down 35% YoY due to pivot.
- Nasdaq listing completed June 12, 2026; $7.8m PIPE funds growth.
- GDT platform advances; IND prep for CD-19 Armed-T targeted for 1Q2027.
- Cash at year-end 2025: $1.26m, down from $4.14m.
- Management pivoted Asia distribution; more focus on R&D and clinical assets.
Companies Mentioned
- Horizon Space Acquisition II Corp (N/A): Completed SL Science business combination; Nasdaq listing enabled and PIPE financing facilitated funding.
- SL Science Holding Limited (SLBT): Listed on Nasdaq Global Market (ticker SLBT); driving GDT/CD-19 programs with recent financing.
- Taiwan TFDA (N/A): Regulatory interactions ongoing; May 2026 import review docs submitted for clinical-grade reagents.
Corporate Developments
Category: Corporate Developments. The news centers on a completed business combination, Nasdaq listing, and funding activity with operational pivots and regulatory milestones shaping SLBT's near-term path.